Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2017)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance

  • Xiaoyun Lu,
  • Zhang Zhang,
  • Xiaomei Ren,
  • Deping Wang,
  • Ke Ding

DOI
https://doi.org/10.1080/14756366.2016.1250757
Journal volume & issue
Vol. 32, no. 1
pp. 331 – 336

Abstract

Read online

Bcr-AblT315I induced drug resistance remains a major challenge to chronic myelogenous leukemia (CML) treatment. Herein, we reported GZD856 as a novel orally bioavailable Bcr-AblT315I inhibitor, which strongly suppressed the kinase activities of both native Bcr-Abl and the T315I mutant with IC50 values of 19.9 and 15.4 nM, and potently inhibited proliferation of corresponding K562, Ba/F3WT and Ba/F3T315I cells with IC50 values of 2.2, 0.64 and 10.8 nM. Furthermore, GZD856 potently suppressed tumor growth in mouse bearing xenograft K562 and Ba/F3 cells expressing Bcr-AblT315I. Thus, GZD856 may serve as a promising lead for the development of Bcr-Abl inhibitors overcoming acquired imatinib resistance.

Keywords